Search company, investor...



Acquired | Acquired

Total Raised


About OncoTherapeutics

OncoTherapeutics develops cancer diagnostics and therapeutics based on Kallikrein family of proteins.

Headquarters Location

Cranbury, New Jersey,

United States

Missing: OncoTherapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: OncoTherapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing OncoTherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OncoTherapeutics is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

OncoTherapeutics Frequently Asked Questions (FAQ)

  • Where is OncoTherapeutics's headquarters?

    OncoTherapeutics's headquarters is located at Cranbury.

  • What is OncoTherapeutics's latest funding round?

    OncoTherapeutics's latest funding round is Acquired.

  • How much did OncoTherapeutics raise?

    OncoTherapeutics raised a total of $140K.

  • Who are the investors of OncoTherapeutics?

    Investors of OncoTherapeutics include Biomira and Domain Associates.

  • Who are OncoTherapeutics's competitors?

    Competitors of OncoTherapeutics include Igenica Biotherapeutics, Veracyte, Sopherion, Critical Therapeutics, Neomics and 8 more.

Compare OncoTherapeutics to Competitors


Sopherion is a therapeutics platform company initially focused on cancer.


Neomics is a drug discovery and diagnostics company with a unique cancer target and biomarker discovery platform. In particular, Neomics is focused on novel targets and biomarkers relevant to aminoacyl RNA synthetases (ARS). They have preclinical and clinical validation of their targets and biomarkers.

Falcon Genomics

Falcon Genomics, Inc. is focused on functional genomics as a tool for cancer diagnostics and therapeutics.


Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA

Pro-Cure Therapeutics

Prostate Cancer - Pro-Cure Therapeutics - Enabling the development of a cure for prostate cancer based on stem cells


NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.